000 02327cam a2200337 a 4500
003 EG-GiCUC
005 20250223031104.0
008 141110s2014 ua d f m 000 0 eng d
040 _aEG-GiCUC
_beng
_cEG-GiCUC
041 0 _aeng
049 _aDeposite
097 _aM.Sc
099 _aCai01.11.18.M.Sc.2014.Ra.A
100 0 _aRasha Refaat Mohammad Aly
245 1 0 _aAllogeniec peripheral blood stem cell transplantation in patients with severe aplastic anemia, comparing fludarabine based versus anti - thymocyte globuline based conditioning regimens :
_bA retrospective study /
_cRasha Refaat Mohammad Aly ; Supervised Omar Abdelrahman Fahmy , Raafat Mohammad Abdelfattah
246 1 5 _aزراعة النخاع العظمى من متبرع باستخدام خلايا النخاع الجذعية الطرفية لمرضى فشل النخاع العظمى: مقارنة بين استخدام عقار الفلودارابين و استخدام جلوبيين مضاد الخلايا الثيموسية :
_bدراسة استعادية
260 _aCairo :
_bRasha Refaat Mohammad Aly ,
_c2014
300 _a177 P. :
_bcharts ;
_c25cm
502 _aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Internal Medicine
520 _aAllogeneic hematopoietic stem cell transplantation (Allo - HSCT) from an HLA matched sibling donor is the initial treatment of choice for newly diagnosed patients with severe aplastic anemia. Regarding the graft type, in 2007 The American society of hematology published data, indicating that BM grafts are preferred to PBPC grafts in young patients undergoing HLA - matched sibling donor transplantation for SAA. The conditioning regimen In order to improve survival in patients older than 30-40 years, the use of less cytotoxic but more immunosuppressive regimens including low - dose cyclo - phosphamide in combination with ATG, while adding fludarabine (Flu), might be an option
530 _aIssued also as CD
653 4 _aConditioning regimen
653 4 _aFludarabine
653 4 _aSevere aplastic anemia
700 0 _aOmar Abdelrahman Fahmy ,
_eSupervisor
700 0 _aRaafat Mohammad Abdelfattah ,
_eSupervisor
856 _uhttp://172.23.153.220/th.pdf
905 _aNazla
_eRevisor
905 _aSamia
_eCataloger
942 _2ddc
_cTH
999 _c48140
_d48140